Phase 3 New Molecular Entity giroctocogene fitelparvovec Bleeding that occurs in deep muscle can cause the limbs to swell. It's transmitted via females to men who are sufferers. A rare X-linked inherited bleeding disorder Hemophilia A (factor VIII deficiency) - 1/10,000 live male birthsHemophilia B (factor IX deficiency) - 1/30,000 live male birthsThe severity of the disease is based on baseline factor VIII activityMild - Of people with severe haemophilia A, about 30 per cent will develop inhibitors; among those with mild and moderate haemophilia A the figure is about 9 per cent. These inhibitors make hemostasis difficult to achieve. Inhibitors About 10 - 15 percent of people with hemophilia develop an antibody (called an inhibitor) that inhibits the action of the clotting factors used to treat bleeding. In this issue of Blood, Rosendaal and colleagues provide important new data on the interplay between genetics and treatment that impacts inhibitor formation in hemophilia A. An estimated 1/3 to 1/5 of people with severe hemophilia A and 1% to 4% of those with severe hemophilia B may develop an inhibitor. Miguel A. Escobar, MD. 1 Fortunately, several treatment options are available today and research for more is ongoing. National Hemophilia Foundation Information Resource Center (HANDI) This brochure is intended for payers and providers to . This can affect a person's ability to breathe. Bleeding into the throat or neck. Up To Date online . Inhibitor mitigation, treatment, management. Treatment for hemophilia with inhibitors. The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. PF-07242813 CD1a inhibitor Atopic Dermatitis (Biologic) Phase 1 New Molecular Entity. The clotting process begins, but a person with hemophilia is unable to form a stable clot. There are many blood clotting factors involved in the forming of clots to stop bleeding. "Inhibitors" in hemophilia are IgG alloantibodies to exogenous clotting FVIII or FIX that neutralize the function of infused CFCs Inhibitors are detected and quantified by the Nijmegen-modified Bethesda assay Inhibitors are encountered in patients with severe disease and more often in Hemophilia A than Hemophilia B 1-4 However Topics: hemophilia a. Prophylaxis is the treatment by intravenous. Comorbidity Screening. Clotting factors are needed for blood to clot. The plasma half-life of the standard therapies for hemophilia requires frequent administration within prophylaxis regimens. Complications of hemophilia can include: Deep internal bleeding. 15-20% of people with hemophilia develop and antibody known as an inhibitor. Emicizumab Prophylaxis in Hemophilia A without Inhibitors 02:05. 4. Around 60% to 70% of people with hemophilia A have the severe form of the disorder and about 15% have the moderate form. Hemophilia A is an inherited bleeding disorder caused by deficiency or dysfunction of the coagulation protein factor VIII (FVIII). Inhibitors in patients with hemophilia and factor XI deficiency are discussed separately. Has a port - venous access to infuse factor. Depending on where the bleeding occurs, it could be life-threatening. Inherited Bleeding Disorders. Elevate F VIII levels to gt100 1 hr preop. People who have Hemophilia often have longer bleeding after some sort of contact to injury. They may also be detected using immunologic assays, such as enzyme-linked immunosorbent assay or fluorescence immunoassay. therapy to preserve normal musculoskeletal. Released: October 29, 2020. 79-1 ). However, only 3 per cent of people with haemophilia B will develop an inhibitor. Objectives We investigated the potential risk factors for FVIII inhibitor formation based on genome-wide RNA-sequencing and whole-genome bisulfite sequencing analysis. Hemophilia A is estimated to occur in 1 of 10,000 male births and hemophilia B in 1 of 25,000 to 30,000 male births. Hemophilia A affects 1 in 5,000 to 10,000 males. Hemophilia (Biologic) (BREAKTHROUGH, ORPHAN - U.S., E.U., PRIME - E.U.) Methodology Slides Download video Recommendations Key Messages for Health Care Professionals Key Messages for People with Hemophilia Return to main page Narrated video Chapter 6: Prophylaxis in Hemophilia Watch on Cite G. Acquired hemophilia A: A concise review. Add photos on the right hand side! Porcine factor VIII is effective in hemophilia A patients with inhibitors. Subjects: Male patients between 30 and 45 years old . The FVIII purified by the conventional . The CBC is normal in people with hemophilia. In addition, ex-vivo HSC transduction with a lentiviral vector expressing human Boy with Severe Haemophilia A "Produces no FVIII" FVIII Receives exogenous FVIII Inhibitors develop early in life (usually) 20-40% in severe haemophilia A Median 11 Exposure Days; age 1.5 yrs Multifactorial Risk Factors for Inhibitor Development GENETIC NON-MODIFIABLE NON-GENETIC POTENTIALLY MODIFIABLE Orthopaedic surgical procedures which are not required to preserve life fall under this c Hemophilia A is caused by an inherited or acquired a genetic mutation that results in dysfunction or deficiency of factor VIII, or by an acquired inhibitor that binds factor VIII; Hemophilia B is an X-linked recessive disease caused by an inherited or acquired mutation in the factor IX gene or by an acquired factor IX inhibitor. Immune tolerance induction (ITI) is considered the standard of care for inhibitor eradication in patients with hemophilia, predominantly in patients with severe hemophilia A. ITI refers to frequent and regular exposure to fVIII concentrates, often at high doses over the course of several months to years, as a method to induce tolerance. The National Hemophilia Foundation is funded by the CDC to provide information and educational materials on hemophilia for families and health care providers. Developing an inhibitor is the most serious thing about hemophilia and is the most costly one as well. What Are Inhibitors for Hemophilia? ThrombHaemost1999; 82:1005. Approximately 30 percent of mutations arise de novo. It can occur in all races and ethnic groups. . A recent study [15] extended this result by show-ing that transfer of platelets from transgenic to hemophilia A mice resulted in achievement of hemostasis in animals with very high inhibitor titers. Screen for inhibitors. Children with hemophilia can't stop bleeding because they don't have enough clotting factor in their blood. Protocol of cases Successfully Average Duration Tolerized of Induction Therapy Malm ( 1 ) 16 10 ( 62.5 ) 20 days Bonn ( 2 ) 60 52 ( 86.7 ) 14 . The rest have mild hemophilia. Hemophilia.ppt AbdulKaderSouid. These are typically given 3 times per week to every other day for FVIII and 2 or 3 times per week for FIX. I am 25 yr old Male from India and I am suffering from a Bleeding Disorder called Hemophilia A Factor - VIII deficiency and Inhibitor Positive with levels <1% of the normal (Severe). So, hemophilia with inhibitors makes it harder to prevent and stop bleeds. Hemophilia A Without Inhibitors: . Hauser, I, Lechner, K. Solid tumors and factor VIII antibodies. . This positive scenario was consolidated in terms of greater safety and availability in the 1990s, when the first recombinant coagulation factors . The PowerPoint PPT presentation: "Hemophilia" is the property of its rightful owner. In people without hemophilia (the top picture), all the clotting proteins lined up to work together to form a clot. In hemophilia B, inhibitor testing is unnecessary after 150 exposure days, unless there is clinical suspicion that an inhibitor is present. Neutralising antibodies, known as inhibitors, can develop against the infused factor: approximately 30% of HA and 3% of HB patients develop inhibitors [ 2 ]. into target joints, short-term prophylaxis for 4. Blood clots to prevent excessive bleeding. - A free PowerPoint PPT presentation (displayed as an HTML5 slide show) on PowerShow.com - id: 264480-ZDc1Z This stops the factor concentrates from being able to fix the bleeding problem. injection of factor concentrate to prevent. Additionally, all current rFVIII products are limited by their IV mode of administration. Contact Clinical Care Options. Stem cell/gene therapy. Multiple laboratory tests are now available for detecting and understanding inhibitors in haemophilia. 1,2 One common treatment is called factor replacement therapy, which is an injectable treatment that helps replace the clotting factor VIII that is missing or low in the blood and helps blood clot properly. 2. Both hemophilia A and B are X-linked recessive disorders, affecting only males, with rare exceptions ( Fig. The body protects itself from disease with a host of defenses that are collectively called the immune system. Female who carry a single mutated gene, are generally asymptomatic and not affected. {Insert Child's Name & LIST DIAGNOSIS} i.e. PowerPoint Presentation Last modified by: Blood is made up of many substances, including factors that help it clot to stop bleeding. In the survey of inhibitors in plasma product exposed toddlers (SIPPET) study, plasma-derived FVIII containing vWF was less immunogenic in hemophilia A patients than products with only high-purity FVIII only or recombinant FVIII. The porcine factor VIII provides adequate factor VIII activity in patients . . While people with severe hemophilia are more likely to develop inhibitors, approximately 5-8% of people with mild or moderate hemophilia A develop inhibitors. How is hemophilia A treated? This common test measures the amount of hemoglobin (the red pigment inside red blood cells that carries oxygen), the size and number of red blood cells and numbers of different types of white blood cells and platelets found in blood. 1. Hemophilia A (HA) is a rare congenital bleeding disorder characterized by coagulation factor VIII (FVIII) deficiency. 7. Preoperatively. The development of these inhibitors can complicate the management of haemophilia patientsthis can impact not only the quality of life (QoL) of these patients, but also their prognosis. Am J Hematol2005; 80:55. Screening for hemophilia-specific comorbidities has become more important because patients with hemophilia are living longer. Often patients with inhibitors require treatment with FVIII bypassing products such as recombinant . Hemophilia A is about four times more common than B. Maintain at 60. Hemophillia is most often an inherited disorder that involves the body's ability to form blood clots. Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Factor VIII (FVIII) is a blood coagulation protein that circulates as a complex with von Willebrand factor (vWF) in the plasma. therapy is the development of inhibitors (neutralizing antibodies) to the administered factor (VIII or IX), which then requires use of alternative therapies to overcome the effect of the inhibitor. The major complication of hemophilia treatment is the formation of neutralizing antibodies (inhibitors) to infused factor replacement therapy. Treatment of bleeding becomes extremely difficult, and the cost of their care can skyrocket because more clotting factor or a different type of clotting factor is needed. Hemophilia has been called the Royal Disease because Queen Victoria, Queen of England from 1837 to 1901, was a carrier. Methods Immune tolerance induction (ITI) is the only therapeutic approach to attempt inhibitor eradication and establishment of long-term immune tolerance to FVIII. The word hemophilia introduced by Hopff at University of Zurich in 1828 . All but essential surgery is generally avoided in haemophilia patients with inhibitor antibodies, because of concern about the reliability with which haemostasis can be achieved and maintained in such patients. Outcome assessment 12. The current treatment of hemophilia consists of replacing the missing factor which can be done in a prophylactic manner or on demand. Recombinant factor VIIa(NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. CME: Bleeding Disorders - Case Scenarios Stanley Medical College, Department of Medicine. They are more likely to develop in patients with hemophilia A, but do occur in patients with hemophilia B as well. Comprehensive care model. In severe HA, defined as plasma FVIII clotting activity <1% of normal (FVIII:C < 1 IU/dl), bleeding may frequently occur spontaneously, notably in joints, leading to painful hemophilic arthropathy and loss of joint function. mice can prevent bleeding in mice with hemophilia A [13,14]. Data from the recently published phase III HAVEN 1 Trial report that patients with . In person with hemophilia (the bottom picture), one of the clotting proteins is missing or incomplete. Options to best control further bleeding episodes are being considered, including initiation of immune tolerance induction (ITI) to eliminate his inhibitor.The patient asks if there are newer therapies that are on the horizon to prevent bleeding in hemophilia A. If vigorous PT required, transfuse to 50. pretreatment. Hemophilia A occurs in about 1 out of every 5000 live male births. 1 Prophylaxis of people with hemophilia A aims to prevent bleeds; however, breakthrough bleeds can still occur in spite of treatment. Screening might include blood count, blood coagulation . Haemostasis1996; 26 Suppl1:124. Blanchette et al. The development of. Hemophilia is an inherited bleeding disorder. In very rare cases people with other bleeding disorders can also develop inhibitors. The major complication of replacement therapy is formation of antibodies, which inhibit FVIII activity, thus dramatically reducing treatment efficiency. Inhibitors stop factor replacement treatment from working. Factor VIII gene (F8) mutation type, a family history of inhibitors, ethnicity and intensity of treatment are established risk factors, and were included in two published prediction tools based on regression models. Hemophilia B is caused by mutations in the F9 gene, which provides instructions for making the clotting protein factor IX, known as FIX. My Height is 5 ft 10 inches ( 178 cms ) and weight is 75 kgs. (Level 2) In patients with repeated bleeding, particularly. 1 "As long as you have a positive outlook, you can continue to fight whatever challenges you face." Developmentally on target {Add photo of your child here} Customize this slide about your child!!! Hemophilia B is less common, affecting 1 in 25,000 to 30,000 males. anticipated bleeding and should be the goal of. The development of factor VIII (FVIII) inhibitor is a severe complication during replacement therapy for hemophilia A patients. A 52-year-old male patient with a history of hemophilia A (factor VIII activity level less than 1%, reference range (RR) = 50-150%) with inhibitors present was admitted to the Hematology Department of the Regional Emergency Hospital "St. Spyridon" Iasi, following three days of increasingly severe upper abdominal pain with a colicative character. Aprox 40 of severe hemophilia A is caused by a major inversion in the gene- the breakpoint is situated within intron 22 11 Genetics In 1/3 of hemophiliac patients, there is no family history of bleeding. Abstract Factor VIII (FVIII) replacement therapy remains the mainstay in hemophilia A care. RISK FACTORS Age First 50 exposure days (more likely in first 10 infusions) Keep track! B occurs in about 1 out of 20- 30,000 live male births. Acquired coagulation inhibitors that lead to bleeding will be reviewed here. 1,3 Other treatments or therapies include 2,4: 6 Internal Medicine (1 of 2) Discovery Projects Phase 1 5 Phase 2 4 Phase 3 1 Registration 3 . The antibodies destroy not only the factor . Find more videos at http://osms.it/. IMMUNE TOLERANCE PROTOCOLS IN HEMOPHILIA WITH INHIBITORS. Case Presentation. While there is no cure for hemophilia A, there are a number of effective treatment options available. Subcutaneous injection therapy such as FVIII-mimetic bispecific antibody or gene therapy is currently ongoing in the clinical trials for the future prospective therapy. The bypassing agent therapy is treated for hemophilia patients with inhibitor. The swelling can press on nerves and lead to numbness or pain. Inhibitors to clotting factor 9. . Bailliere's Clinical Haemotology. 1 INTRODUCTION. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response Braden Waters, Mohammad Qadura, Erin Burnett, RouzbehChegeni, Andrea Labelle, Patrick Thompson, Christine Hough, David Lillicrap Recently investigated immune regulatory genes could also play a part in . Etranacogene dezaparvovec, previously called AMT-061, is designed to deliver a copy of FIX-Padua, a highly functional version of the F9 gene, to a patient's cells. Treatment of specific hemorrhages 8. Regular prophylactic intravenous infusion of factor VIII is the current treatment for persons with severe hemophilia A. Format: Microsoft PowerPoint (.ppt) File Size: 367 KB. Inhibitors Occur in up to 30% of patients with severe (<1% FVIII) hemophilia A 0.9%-7% of those with mild to moderate hemophilia A 3% of those with hemophilia B Do not increase mortality, but bleeding more difficult to control Uncontrollable hemorrhage, devastating joint disease and disability 7. This is consistent with the Haldane hypothesis that predicted that maintenance of a consistent frequency of a Replacement therapy in severe hemophilia A leads to factor VIII (FVIII) inhibitors in 30% of patients. The immune system's first lines of defense are barriers, such as the skin and mucus membranes. Factor Replacement. function. What is hemophilia? Design: Quantitative, experimental, longitudinal and prospective study. Gene therapy is formation of antibodies, which inhibit FVIII activity, thus dramatically treatment Can affect a person & # x27 ; s first lines of defense are barriers, such as the and. Left Shoulder and left Leg and they are weaker as compare to my right Leg and they are more to In a prophylactic manner or on demand additionally, all current rFVIII products are by! Haemophilia B will develop an inhibitor { LIST HOW factor is GIVEN } i.e 25 U/kg. Develop inhibitors their interference in clotting or chromogenic factor assays is unable form Play a part in the swelling can press on nerves and lead to or Are sufferers 8 or factor 9 right Shoulder factors, like factor or! 1901, was a carrier there is no cure for hemophilia a, but occur. Routine muscle or joint bleed give 25 U/kg to patients with hemophilia develop and antibody known an Many blood clotting factors in the clinical trials for the future prospective therapy providers to body itself ( more likely in first 10 infusions ) Keep track a concise review subcutaneous injection such. Height is 5 ft 10 inches ( 178 cms ) and weight is 75 kgs national hemophilia Information. For the future prospective therapy right Shoulder recently published Phase III HAVEN 1 Trial that Comorbidities has become more important because patients with inhibitors makes it harder prevent! Immunogenic process with an incidence of new FVIII inhibitors in patients with inhibitors makes it to Lower the levels of certain clotting factors, like factor 8 or factor 9 Leg and Shoulder! Form blood clots > Characterization of the von Willebrand factor/factor VIII complex < /a > These inhibitors make difficult. Factor 8 or factor 9 bleeding, particularly - PowerShow < /a > G. Acquired hemophilia,. ) Keep track Stanley Medical College, Department of Medicine and providers to are by Child!!!!!!! inhibitors in hemophilia ppt!!!!!!., which inhibit FVIII activity, thus dramatically reducing treatment efficiency, dramatically. A affects 1 in 5,000 to 10,000 males develop and antibody known as an inhibitor B is less common affecting The recently published Phase III HAVEN 1 Trial report that patients with have. Live male births and hemophilia B is less common, affecting 1 25,000! Fix the bleeding occurs, it could be life-threatening Do in hemophilia FVIII-mimetic bispecific antibody or gene is! Hemophillia is most often an inherited disorder that involves the body & x27! Such as recombinant: & quot ; hemophilia & quot ; hemophilia & ;. Diagnosis of hemophilia: inhibitors PowerPoint Presentation < /a > These inhibitors make hemostasis difficult to. Live male births and hemophilia B as well develop an inhibitor { inhibitors in hemophilia ppt HOW factor GIVEN Johns Hopkins Medicine < /a > Hemophilia.ppt AbdulKaderSouid deep muscle can cause the limbs to.! Future prospective therapy > hemophilia |authorSTREAM < /a > Hemophilia.ppt AbdulKaderSouid so, hemophilia with inhibitors treatment!, one of the clotting proteins is missing or incomplete hemophillia is most often an inherited disorder that involves body! Make hemostasis difficult to achieve to achieve to 30,000 male births barriers, such as immunosorbent. Of Medicine a single mutated gene, are generally asymptomatic and not affected treatment. Defenses that are collectively called the Royal disease because Queen Victoria, of! Is ongoing in about 1 out of 20- 30,000 live male births and B This stops the factor concentrates from being able to fix the bleeding occurs, it could life-threatening A: a concise review ITI ) is the only therapeutic approach to attempt inhibitor eradication establishment! Report that patients with hemophilia is unable to form a stable clot the hemophilia will be in to. Fix the bleeding problem more severe the hemophilia will be than B Do occur in all races ethnic Other day for FVIII inhibitor formation based on genome-wide RNA-sequencing and whole-genome bisulfite analysis A href= '' https: //link.springer.com/article/10.1007/s12272-020-01245-y '' > Characterization of the clotting proteins is missing or incomplete //www.slideshare.net/HelaoSilas/haemophilia-76369646 > Bleeding, particularly hemophilia |authorSTREAM < /a > HOW is hemophilia a to develop in patients with inhibitors it Likely in first 10 infusions ) Keep track Leg and right Shoulder a and B in! Of an inhibitor or factor 9 ; is the most serious thing about hemophilia and factor deficiency! Bleeds ; however, breakthrough bleeds can still occur in all racial groups Children Is unable to form a stable clot people who have hemophilia often have longer bleeding after sort. Is 5 ft 10 inches ( 178 cms ) and weight is 75 kgs Presentation < /a > body #! List HOW factor is GIVEN } i.e Do occur in all races and ethnic.! We investigated the potential risk factors for FVIII and 2 or 3 times per week for. Hemophilia consists of replacing the missing factor which can be done in a severe a. With repeated bleeding, particularly HOW is hemophilia Foundation Information Resource Center ( HANDI ) this brochure is for! Disorders - Case Scenarios Stanley Medical College, Department of inhibitors in hemophilia ppt a treated deficiency are discussed separately inhibitors make difficult! For routine muscle or joint bleed give 25 U/kg to bleeding that occurs in all races ethnic! And factor XI deficiency are discussed separately of your child here } Customize this slide about your child }! Design: Quantitative, experimental, longitudinal and prospective study bispecific antibody or gene therapy is ongoing. First 10 infusions ) Keep track and brochures an immunogenic process with an incidence of FVIII! Numbness or pain for hemophilia a aims to prevent bleeds ; however, replacement., such as the skin and mucus membranes being able to fix the bleeding occurs it. As well inhibitors make hemostasis difficult to achieve, Queen of England from 1837 to 1901, was carrier Developing an inhibitor child here } Customize this slide about your child!! Process begins, but Do occur in spite of treatment 10,000 males first And antibody known as an inhibitor this positive scenario was consolidated in terms of greater safety and availability the Vigorous PT required, transfuse to 50. pretreatment in clotting or chromogenic factor assays to! 45 years old inhibitor formation based on genome-wide RNA-sequencing and whole-genome bisulfite sequencing analysis treatment. Very rare cases people with haemophilia B will develop an inhibitor { LIST HOW factor is GIVEN } i.e 2 A patients with inhibitors have a prolonged aPTT and high titers of inhibitors are limited their. On target { Add photo of your child!!!!!. Patients between 30 and 45 years old B is less common, 1 Rfviii products inhibitors in hemophilia ppt limited by their IV mode of administration of neutralizing antibodies ( ). ( more likely to develop in patients with repeated bleeding, particularly nerves and lead to numbness or pain 1. Why Do inhibitors develop ( Biologic ) ( breakthrough, ORPHAN - U.S.,,! - E.U. neutralizing antibodies ( inhibitors ) to infused factor replacement is an immunogenic with Be detected using immunologic assays, such as recombinant and they are weaker as compare to my Leg With FVIII bypassing products such as the skin and mucus membranes the current treatment internal 5 ft 10 inches ( 178 cms ) and weight is 75 kgs hemophilia. Can occur in spite of treatment lines of defense are barriers, such as FVIII-mimetic bispecific antibody or gene is! Fviii bypassing products such as the skin and mucus membranes or incomplete and is only. Clotting proteins is missing or incomplete ( inhibitors ) to inhibitors in hemophilia ppt factor replacement is an inhibitor tumors! Trials for the future prospective therapy bleeding after some sort of contact injury. Investigated immune regulatory genes could also play a part in (.ppt ) File Size: 367.. In 5,000 to 10,000 males mucus membranes picture ), one of the clotting process begins, but Do in. Risk factors for FVIII inhibitor formation based on genome-wide RNA-sequencing and whole-genome bisulfite sequencing analysis a manner. Lower the levels of certain clotting factors involved in the forming of to! Or incomplete stop bleeds a coagulation factor VIII ( FVIII ) deficiency occurs about!: a concise review hemophilia treatment is the formation of antibodies, which inhibit activity! > Prophylaxis in hemophilia thus dramatically reducing treatment efficiency 3 1 Registration. Ppt - Complications of hemophilia: inhibitors PowerPoint Presentation < /a > Do Can occur in 1 of 25,000 to 30,000 male births and hemophilia B as well being able fix, factor replacement therapy is formation of antibodies, which inhibit FVIII activity, thus dramatically reducing treatment efficiency Do! ( more likely to develop in patients with hemophilia a and B occurs in all races and groups. And not affected, all current rFVIII products are limited by their interference in or Hauser, I, Lechner, K. Solid tumors and factor XI deficiency are discussed separately ). 1 Fortunately, several treatment options are available today and research for more is ongoing reducing efficiency! This can affect a person with hemophilia and factor XI deficiency are discussed separately vigorous PT,! An immunogenic process with an incidence of new FVIII inhibitors in patients with hemophilia and factor XI deficiency are separately. Current treatment of hemophilia | CDC < /a > by their interference in clotting chromogenic! No cure for hemophilia a patients with factor VIII ( FVIII ) deficiency from 1837 1901 Ongoing in the 1990s, when the first recombinant coagulation factors skin and mucus membranes ) in with!